Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zenapax-activated peptide immunotherapy.

Next Previous
Search
Trial Profile

Zenapax-activated peptide immunotherapy.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Basiliximab (Primary) ; Daclizumab; PEP-3-KLH conjugate vaccine; Temozolomide
  • Indications Glioblastoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ZAP IT

Most Recent Events

  • 29 Mar 2011 Planned end date changed from 1 Nov 2010 to 1 Nov 2013 as reported by ClinicalTrials.gov.
  • 28 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 06 Jun 2010 Basiliximab added as investigational drug as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top